As of 2026-04-03, the EV/EBITDA ratio of Outlook Therapeutics Inc (OTLK) is -0.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OTLK's latest enterprise value is 57.37 mil USD. OTLK's TTM EBITDA according to its financial statements is -103.81 mil USD. Dividing these 2 quantities gives us the above OTLK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 16.7x | 14.5x |
| Forward P/E multiples | 17.7x - 21.0x | 19.7x |
| Fair Price | (13.92) - (13.10) | (13.44) |
| Upside | -6454.4% - -6080.0% | -6235.4% |
| Date | EV/EBITDA |
| 2026-04-02 | -0.55 |
| 2026-04-01 | -0.54 |
| 2026-03-31 | -0.54 |
| 2026-03-30 | -0.53 |
| 2026-03-27 | -0.54 |
| 2026-03-26 | -0.54 |
| 2026-03-25 | -0.54 |
| 2026-03-24 | -0.53 |
| 2026-03-23 | -0.68 |
| 2026-03-20 | -0.72 |
| 2026-03-19 | -0.70 |
| 2026-03-18 | -0.72 |
| 2026-03-17 | -0.78 |
| 2026-03-16 | -0.72 |
| 2026-03-13 | -0.78 |
| 2026-03-12 | -0.81 |
| 2026-03-11 | -0.83 |
| 2026-03-10 | -0.84 |
| 2026-03-09 | -0.85 |
| 2026-03-06 | -0.80 |
| 2026-03-05 | -0.83 |
| 2026-03-04 | -0.84 |
| 2026-03-03 | -0.81 |
| 2026-03-02 | -0.82 |
| 2026-02-27 | -0.81 |
| 2026-02-26 | -0.83 |
| 2026-02-25 | -0.84 |
| 2026-02-24 | -0.80 |
| 2026-02-23 | -0.79 |
| 2026-02-20 | -0.80 |
| 2026-02-19 | -0.83 |
| 2026-02-18 | -0.80 |
| 2026-02-17 | -0.82 |
| 2026-02-13 | -0.90 |
| 2026-02-12 | -0.84 |
| 2026-02-11 | -0.88 |
| 2026-02-10 | -0.81 |
| 2026-02-09 | -0.79 |
| 2026-02-06 | -0.82 |
| 2026-02-05 | -0.77 |
| 2026-02-04 | -0.79 |
| 2026-02-03 | -0.83 |
| 2026-02-02 | -0.84 |
| 2026-01-30 | -0.84 |
| 2026-01-29 | -0.86 |
| 2026-01-28 | -0.85 |
| 2026-01-27 | -0.91 |
| 2026-01-26 | -0.93 |
| 2026-01-23 | -0.92 |
| 2026-01-22 | -0.93 |